ArticleBMC ophthalmology2025
Evaluation of blood-count-derived inflammatory markers in patients with idiopathic epiretinal membrane.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Systemic inflammatory response index as a predictive biomarker for Irvine-Gass syndrome.International ophthalmology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo assess the role of inflammation in the pathogenesis of idiopathic epiretinal membrane (iERM) by evaluating blood-count-derived inflammatory marker levels.
methodsThe medical records of patients diagnosed with iERM and cataract patients with normal fundus examinations were analyzed retrospectively. Levels of neutrophils, monocytes, lymphocytes, and thrombocytes were obtained from blood samples. Systemic inflammatory markers, including neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and systemic inflammatory response index (SIRI) were calculated and compared between the two groups. The receiver operating characteristic curve (ROC) analysis was performed to determine the best cutoff value of NLR, PLR, SII, and SIRI in iERM.
resultsIn total, 91 iERM cases and 95 controls were included in the study. iERM patients had significantly higher NLR (2.25 vs. 1.91, p = 0.003), PLR (117.22 vs. 113.33, p = 0.042), SII (529.45 vs. 472.57, p = 0.003), and SIRI (1.25 vs. 0.90, p < 0.001). The area under the curve of NLR, PLR, SII, and SIRI in differentiating patients with iERM and controls was 0.637, 0.608, 0.645 and 0.660, respectively, according to ROC analysis. The best cutoff values (with sensitivity and specificity) were 1.95 (60.4% and 52.6%) for NLR, 116.7 (54.9% and 55.7%) for PLR, 498.03 (58.2% and 58.9%) for SII, and 1.07 (62.6% and 64.6%) for SIRI.No significant differences in inflammatory markers were found across iERM stages.
conclusionPatients with iERM exhibit higher levels of blood-count-derived inflammatory markers, suggesting a link between systemic subclinical inflammation and iERM development. However, these markers do not correlate with iERM severity. Further research with larger cohorts and broader inflammatory marker analysis is needed to elucidate the role of systemic inflammation in iERM pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.